Premium
In vitro evaluation of adhesion of adipose‐derived adult stem cells to chitosan for the treatment of ocular surface pathologies
Author(s) -
PASTOR S,
ALIO SANZ JL,
GAMBOAMARTINEZ TC,
ARNALICHMONTIEL F,
DE MIGUEL MP,
GOMEZRIBELLES JL,
GALLEGOFERRER G
Publication year - 2008
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2008.6237.x
Subject(s) - chitosan , extracellular matrix , adhesion , adipose tissue , cell adhesion , biomedical engineering , tissue engineering , materials science , chemistry , in vitro , microbiology and biotechnology , medicine , biochemistry , biology , composite material
Purpose To analyze the ability of adhesion of adipose‐derived adult stem cells (ADAS) to porous materials made of chitosan for the future design of biodegradable autologous membranes for the treatment of ocular surface pathologies Methods We used porous chitosan scaffolds prepared by cold neutralization in a 4% chitosan aqueous solution at acid pH, some of the materials were treated with argon plasma to favour cell adhesion. ADAS cells were obtained after adipose tissue processing from patients undergoing liposuction surgery. 5,000 cells were seeded per each scaffold in DMEM/F12 medium and cellular growth was analyzed on these materials by scanning electron microscopy (SEM) after ten days in culture. Results Adhesion was observed and cell growth was optimal on the surface of non‐plasma‐treated biomaterials. Chitosan scaffolds treated with argon plasma showed better adhesion properties. Extracellular matrix production was also observed Conclusion 4% chitosan biomaterials allow for adhesion, proliferation and extracellular matrix production of ADAS cells. Biocolonization of these biomaterials with ADAS cells will imply the future design of biological autologous membranes containing cells from the very same patient that would act as patches for the treatment of ocular surface pathologies for which current treatments show certain risks such immune rejection, infections or low effectivity.